Jupiter Wellness, Inc. (JUPW)
Chart Events
Performance Outlook
| Previous Close | 0.8100 |
| Open | 0.8643 |
| Bid | 0.8576 x 1000 |
| Ask | 0.8756 x 1100 |
| Day's Range | 0.8131 - 0.9000 |
| 52 Week Range | 0.6300 - 8.8800 |
| Volume | |
| Avg. Volume | 899,327 |
| Market Cap | 20.338M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- Jupiter Wellness, Inc.Daily – Vickers Top Buyers & Sellers for 10/08/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat4 months agoArgus Research
- ACCESSWIRE
Jupiter Wellness Announces Board Approval of $5.0 Million Share Buyback Program
Represents Approximately 30% of Jupiter Wellness's Outstanding Shares at current market priceJUPITER, FL / ACCESSWIRE / January 25, 2022 / Jupiter Wellness, Inc. (NASDAQ:JUPW) today announced it its board of directors approved a $5.
- ACCESSWIRE
Jupiter Wellness to Dividend SRM Entertainment Subsidiary to its Stockholders
SRM Entertainment to raise up to $10 million and seek listing on Nasdaq Creates a "Pure Play" Drug Developer in Jupiter Wellness upon the Completion of its Pending Merger with Next Frontier PharmaceuticalsJUPITER, FL / ACCESSWIRE / January 24, 2022 / Jupiter Wellness, Inc. (NASDAQ:JUPW) today announced it intends to dividend its wholly-owned subsidiary, SRM Entertainment to its stockholders in conjunction with Jupiter Wellness' merger with Next Frontier Pharmaceuticals, Inc.
- ACCESSWIRE
Jupiter Wellness' Merger Partner Next Frontier Pharmaceuticals, Inc. Enters Psychedelic Drug Development and API Market
Next Frontier Pharmaceuticals' Subsidiary Benuvia Signs Agreement with Global Wellness' Shanti Therapeutics * Benuvia has begun focusing on Psilocybin, DMT, and MDMA. * Benuvia's 83,000 square foot synthetic compound manufacturing facility is permitted by the U.
